Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Rhea-AI Summary

Arvinas (NASDAQ: ARVN) will present preclinical data for its PROTAC BCL6 degrader ARV-393 in combination with glofitamab at the 2025 American Society of Hematology (ASH) Annual Meeting.

The poster (Publication No. 1520) is in Session 605: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I, on December 6, 2025, 5:30 PM–7:30 PM ET, at OCCC – West Halls B3–B4. The full abstract is available via the ASH online program.

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for PROTAC BCL6 degrader ARV-393, in combination with glofitamab, a CD20xCD3 bispecific antibody, will be presented in a poster presentation at the 2025 American Society of Hematology (ASH) Annual Meeting, being held December 6–9, 2025, in Orlando, Florida.

The presentation details are as follows:

• Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I
• Date: December 6, 2025
• Time: 5:30 PM – 7:30 PM ET
• Room: OCCC – West Halls B3–B4
• Publication Number: 1520
  

The full abstract can be accessed via the ASH online program.

About ARV-393

ARV-393 is an investigational PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas. The BCL6 protein facilitates B cell tolerance of rapid proliferation and somatic gene recombination via repressing cell cycle checkpoints, terminal differentiation, apoptosis, and the DNA damage response. PROTAC-mediated degradation has the potential to address the traditional undruggable nature of BCL6. ARV-393 is currently being evaluated in a Phase 1 clinical trial in patients with non-Hodgkin lymphoma.

About Arvinas

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of ARV-393 and the potential of PROTAC-mediated degradation to address the traditional undruggable nature of B-cell lymphoma 6 protein. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “target,” “goal,” “potential,” “will,” “would,” “could,” “should,” “look forward,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete clinical development for its product candidates, including ARV-393; risks related to Arvinas’ expectations regarding the potential clinical benefit of our product candidates, including ARV-393; uncertainties relating to regulatory applications and related approval timelines; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

FAQ

When will Arvinas present ARV-393 preclinical data at ASH 2025 (ARVN)?

Arvinas will present on December 6, 2025 from 5:30 PM–7:30 PM ET in OCCC – West Halls B3–B4.

What is the ASH 2025 session and publication number for Arvinas ARV-393 (ARVN)?

The poster is in Session 605 (Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I) and is Publication No. 1520.

What combination was studied with ARV-393 in the ASH 2025 poster by Arvinas (ARVN)?

The preclinical poster reports ARV-393 in combination with glofitamab, a CD20xCD3 bispecific antibody.

Where can investors access the full ARV-393 abstract for ASH 2025 (ARVN)?

The full abstract can be accessed via the ASH online program.

What type of data will Arvinas present for ARV-393 at ASH 2025 (ARVN)?

Arvinas will present preclinical data for the PROTAC BCL6 degrader ARV-393 in combination with glofitamab.